AMERICAN SOCIETY FOR MICROBIOLOGY

47TH icaac chicago September 17-20, 2007

SERGE TCHAMGOUE
CH
tchamgou@club-internet.fr
serge.tchamgoue@ch-libourne.fr
Libourne, 33500
France
Fax: (33) 5 57 55 35 69
Email: tchamgou@club-internet.fr

Dear Dr. TCHAMGOUE:

On behalf of the American Society for Microbiology and the ICAAC Program Committee, we are pleased to inform you that your abstract has been accepted for a poster presentation at the 47th ICAAC. Following is pertinent information for planning your attendance. Please be sure to share this information with the co-authors on this abstract. In addition, a listing of all accepted abstract submissions will be available online at: http://www.icaac.org/ beginning Monday, July 9.

Control Number #: 3392
Session # / Title: 026/HIV: Antiretroviral Treatment
Session Type: Poster Session
Presentation Number: H-366
Presentation Title: No Increased Antiretroviral Potency By The Addition Of Enfuvirtide To A Haart Regimen Including Boosted P.i In Naive Hiv-infected Patients, Anrs Co3 Aquitaine Cohort
Session Day / Time: 9/17/2007 1:00:00 PM
Session Location: Hall D

Poster Board Assignment: Your Poster Board Number will be available online via the Online Program Planner in late-July, please be sure to check http://www.icaac.org/ to locate your assigned poster board number for placing your poster presentation.

Posters: The poster board is 4 feet tall x 8 feet wide. In general, posters are displayed from 10:00 a.m. to 4:30 p.m., Monday through Wednesday, and 8:30 a.m. to 11:30 a.m. on Thursday. Your poster MUST remain on display throughout the day on the day your poster is scheduled to be presented. You are scheduled to be available at your poster for 1 hour, beginning at 9/17/2007 1:00:00 PM. Show this letter to Security at the Poster Confirmation desk, to access the poster area between 7:30 a.m. – and 9:30 a.m. Posters must be removed by 5:00 p.m., Monday through Wednesday, and 12:00 noon on Thursday. Please check bags, convention materials, poster tubes, etc. in the Poster Storage area.

Commercial Logos: Commercial logos must NOT be placed on posters or poster boards. Be sure to communicate this if the poster is being prepared for you by someone else.

Poster Guidelines: For tips on preparing successful posters, please visit http://www.icaac.org/. ASM encourages poster presenters to place an email address on posters and poster compilations for post meeting communications.

All authors please note, submission of abstracts was conditional on the assurance that chemical structures of lead compounds would be included as part of any poster or slide accepted for presentation.

Preliminary Program: To review detailed program information, you may access the 47th ICAAC Preliminary Program online at http://www.icaac.org/.

Discounted Meeting Registration:
The discounted pre-registration deadline is July 13, and the final pre-registration deadline is August 17, 2007, after which time you may register on-site. You may register online at http://www.icaac.org/.

Embargo: Please be advised that it is ASM's policy that, while presenters are allowed to communicate with the press, their discussions may not be published until after the day and time of the actual presentation. **In addition, per the rules for abstract submission, the preponderance of the data to be presented should not have been published or presented prior to its presentation at the 47th ICAAC.**

Penalties: By submitting your abstract, you have agreed to present it at ICAAC. If you are unable to present, you should notify ASM via email at icaacpc@asmusa.org or by fax at 202-942-9340, indicating your abstract control number. Please note that you risk not being allowed to present at future ASM meetings, for a period of up to three years, if you 1) fail to present an accepted abstract, 2) present previously published data, or 3) your presentation is promotional in nature.

Sincerely,

386

No increased antiretroviral potency by the addition of Enfuvirtide to a HAART regimen including boosted P.I. in naive HIV-infected patients, ANRS CO3 Aquitaine cohort.

S. Tchamgoué, S. Lawson-Ayayi, F. Dabis, JL Pellegrin

Background : Six months after HAART, current CD4 cells count and viral load (VL), but not values at baseline, are strongly associated with disease progression. We hypothesize that HAART potency might be enhance by combination of enfuvirtide (T20).
Our study aims to assess whether T20 can early enhance a HAART regimen efficiency in naive HIV1-infected patients.
Patients and methods: All naïve patients beginning a HAART regimen (boosted PI with two NRTI or analogous) between 01/01/2004 and 31/12/2006 were included (T20+HAART group). A sample of patients matched by CD4 and VL at baseline, therapeutic criteria, was selected for comparison (HAART group).
We analyzed CD4 and VL evolution six month after HAART initiation.
Results: At baseline, 21 patients were recruited (90.5% male) (table 1). No T20 resistance-associated mutations were identified. The median time of T20 used was 103 days (IQR: 86-117).
At 6 months, in the T20+HAART group, the median CD4 count was 383/mL (IQR: 268-609) *versus* 295/mL (IQR: 159-404) in the HAART group (p=0.12); the percentage of CD4 was 23.2 [16.3-32.1] *versus* 23.4 [15.9-28.4], (p=0.73); VL decline was 4.13 log [3.73-4.48] *versus* 3.92 log [3.48-4.33], (p=0.39).
Conclusion: At 6 months, viral suppression and CD4 cells progression have not been improved by the association of T20 with a HAART regimen including a boosted PI.

Table 1: Patients characteristics at baseline according to patients groups

Characteristics		**HAART group (n = 21)**		**T20+HAART group (n = 21)**		***p***
		n	(%)	n	(%)	
Male gender		14	(66.7)	19	(90.5)	*0.06*
Disease stage	A	14	(66.7)	12	(57.1)	*0.557*
	B	3	(14.3)	2	(9.5)	
	C (AIDS)	4	(19.0)	7	(33.4)	
Transmission group	MSM	10	(47.6)	12	(57.1)	*0.159*
	IDU	1	(4.8)	-		
	Heterosexual	10	(47.6)	6	(28.6)	
	Other	-		3	(14.3)	
		median	[IQR]	median	[IQR]	
Age (years)		42.9	[37.2-50.2]	42.6	[38.9-49.0]	*0.772*
CD4 cells, median (/mL)		176	[83-266]	162	[47-249]	*0.521*
CD4 cells (%)		14.2	[9.9-17.8]	10.6	[4.5-18.4]	*0.414*
VL (copies/mL)		347348	[153101-870330]	527200	[225900-1198000]	*0.517*